Cotrim DS



Indications and Reactions:

Role Indications Reactions
Primary
Urinary Tract Infection 42.9%
Depression 14.3%
Hypothyroidism 14.3%
Neuralgia 14.3%
Ph Urine 14.3%
Circulatory Collapse 28.6%
Intra-uterine Death 28.6%
Petechiae 14.3%
White Blood Cell Count Decreased 14.3%
Wrong Drug Administered 14.3%
Secondary
Prophylaxis 38.7%
Acute Myeloid Leukaemia 22.5%
Multiple Myeloma 9.9%
Refractory Anaemia With An Excess Of Blasts 4.2%
Hiv Infection 3.5%
Drug Use For Unknown Indication 2.8%
Pain 2.8%
Acquired Immunodeficiency Syndrome 2.1%
Extravasation 2.1%
Myelodysplastic Syndrome 2.1%
Product Used For Unknown Indication 2.1%
Urinary Tract Infection 2.1%
Raynaud's Phenomenon 1.4%
Arthritis 0.7%
Chemotherapy 0.7%
Chronic Lymphocytic Leukaemia 0.7%
Dementia 0.7%
Suicide Attempt 0.7%
Nausea 11.5%
Leukopenia 7.7%
Pneumonia 7.7%
Tachycardia 7.7%
Thrombotic Thrombocytopenic Purpura 7.7%
Anuria 3.8%
Cardiomyopathy 3.8%
Dementia 3.8%
Drug Hypersensitivity 3.8%
Exfoliative Rash 3.8%
Hepatitis Acute 3.8%
Pneumonia Cytomegaloviral 3.8%
Rash 3.8%
Renal Failure Acute 3.8%
Sepsis 3.8%
Stem Cell Transplant 3.8%
Sudden Cardiac Death 3.8%
Supraventricular Tachycardia 3.8%
Transaminases Increased 3.8%
Urinary Tract Infection 3.8%
Concomitant
Product Used For Unknown Indication 18.0%
Drug Use For Unknown Indication 17.4%
Hodgkin's Disease 11.3%
Multiple Myeloma 8.2%
Prophylaxis 7.9%
Hiv Infection 4.8%
Chronic Lymphocytic Leukaemia 4.5%
Infection Prophylaxis 3.7%
Pain 3.3%
B-cell Lymphoma 2.8%
Hypertension 2.6%
Diffuse Large B-cell Lymphoma 2.5%
Thrombosis Prophylaxis 2.1%
Renal Transplant 1.9%
Non-hodgkin's Lymphoma 1.8%
Mucosal Inflammation 1.5%
Premedication 1.5%
Acute Myeloid Leukaemia 1.4%
Liver Transplant 1.4%
Plasmacytoma 1.4%
Respiratory Failure 9.2%
White Blood Cell Count Decreased 9.2%
Sepsis 7.9%
Pyrexia 6.6%
Somnolence 6.6%
Malignant Melanoma In Situ 5.3%
Pneumonia 5.3%
Renal Failure Acute 5.3%
Supraventricular Tachycardia 5.3%
Bladder Cancer 3.9%
Cerebral Infarction 3.9%
Febrile Neutropenia 3.9%
General Physical Health Deterioration 3.9%
Haematopoietic Stem Cell Mobilisation 3.9%
Optic Atrophy 3.9%
Pancytopenia 3.9%
Vision Blurred 3.9%
Aggression 2.6%
Bradycardia 2.6%
Femur Fracture 2.6%